Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis

KEY MESSAGES: Considerable proportion of patients with SpA have been immunized to the subcutaneous anti-TNF drug they are using. Concomitant use of MTX protects from immunization, whereas SASP does not. Patients with SpA using subcutaneous anti-TNF drugs can benefit from monitoring of the drug troug...

Descripción completa

Detalles Bibliográficos
Autores principales: Hiltunen, J., Parmanne, P., Sokka, T., Lamberg, T., Isomäki, P., Kaipiainen-Seppänen, O., Peltomaa, R., Uutela, T., Pirilä, L., Taimen, K., Kauppi, M. J., Yli-Kerttula, T., Tuompo, R., Relas, H., Kortelainen, S., Paalanen, K., Asikainen, J., Ekman, P., Santisteban, A., Vidqvist, K.-L., Tadesse, K., Romu, M., Borodina, J., Elfving, P., Valleala, H., Leirisalo-Repo, M., Rantalaiho, V., Kautiainen, H., Jokiranta, T. S., Eklund, K. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Observational Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124652/
https://www.ncbi.nlm.nih.gov/pubmed/34357455
http://dx.doi.org/10.1007/s00296-021-04955-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124652/
https://www.ncbi.nlm.nih.gov/pubmed/34357455
http://dx.doi.org/10.1007/s00296-021-04955-8

Ejemplares similares